Financial News

Financial Report: AMRI

Contract revenue for the quarter up 56%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AMRI 1Q Revenues: $163.8 million (+55%) 1Q Loss: $10.7 million (loss of $10.1 million 1Q16) Comments: Contract revenue for the quarter was $160.2 million, up 56%. Recurring royalty revenue in quarter was $3.6 million, an increase of 31%. Active Pharmaceutical Ingredients (API) revenues were $106.1 million, up from $57.1 million. Discovery, Development and Analytical Services (DDS) revenue was $29.2 million, up 24%. Drug Product (DP) revenue was $23.4 million, down 10% primarily due to t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters